What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

This analysis aimed to assess patient-reported outcomes and satisfaction in psoriatic arthritis patients treated with guselkumab or IL-17 inhibitors.

April 30, 2026Lara D. Veeken

P184 Patient reported impact and satisfaction with guselkumab and IL-17 inhibitors in psoriatic arthritis: 12-month results of the PsABIOnd observational study

View Full Paper

Ask AI

Bookmark

Authors

LGLaure GossecSorbonne Université MSMohamed SharafJohnson & Johnson (United States)XBX BaraliakosRheumazentrum Ruhrgebiet

Discussion

Member takes

Implication

Observational results show high patient satisfaction and significant improvements in psoriatic arthritis outcomes after treatment with guselkumab or IL-17 inhibitors.

Key Points

This analysis aimed to assess patient-reported outcomes and satisfaction in psoriatic arthritis patients treated with guselkumab or IL-17 inhibitors.
Global, observational study in psoriatic arthritis patients starting treatment with guselkumab or IL-17 inhibitors.
Participants assessed at baseline and 12 months for changes in patient-reported outcomes.
Measured patient satisfaction using the Treatment Satisfaction Questionnaire for Medication-9.
Improvements in PsAID-12 total score and patient global assessment reported at 12 months.
High levels of patient satisfaction observed in both treatment groups.
Similar rates of achieving minimal clinically important improvement in both treatment groups.

Cite This Study

Gossec et al. (2026) studied this question.

synapsesocial.com/papers/69f2a4f18c0f03fd677641ce https://doi.org/10.1093/rheumatology/keag121.215

View Full Paper

Ask AI

Bookmark

Implication

Observational results show high patient satisfaction and significant improvements in psoriatic arthritis outcomes after treatment with guselkumab or IL-17 inhibitors.

P184 Patient reported impact and satisfaction with guselkumab and IL-17 inhibitors in psoriatic arthritis: 12-month results of the PsABIOnd observational study

Discussion

Member takes

Implication

Key Points

Cite This Study

P184 Patient reported impact and satisfaction with guselkumab and IL-17 inhibitors in psoriatic arthritis: 12-month results of the PsABIOnd observational study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider